Sickle cell patients have faced ‘poor care' from ambulance staff
Findings of a research project – commissioned by London Ambulance Service (LAS) NHS Trust and carried out by the Sickle Cell Society – into sickle cell patients' experiences of ambulance care and 999 and 111 calls in London revealed that many patients had negative experiences, some historic and some recent, with LAS, which have affected their confidence in the service.
The research found some of the key themes of those who detailed negative experiences included lack of appropriate pain relief, inconsistent care, having to answer too many questions while in acute pain, and not feeling listened to or respected.
Other themes arising included insufficient priority and slow attendance, not being taken to a preferred hospital and issues with handover from LAS to emergency departments.
A joint written submission from four individuals (one sickle cell patient, two parents of young adults with sickle cell, and one widow of a sickle cell patient), who had also sought the views of peers, stated: 'There is a general consensus that the majority of people spoken to are very reluctant to call the ambulance service unless it is the only and last resort and the pain is so bad they have no excuse but to go hospital.
'This is for numerous reasons: fear of not receiving appropriate pain medication en route, not being listened to in terms of what their needs are and perception of being seen as a drug-seeking individual.'
They added that sickle cell patients' views of LAS were often 'marred by past performance'.
The report's recommendations include the LAS routinely involving sickle cell patients in training for its staff and ensuring that staff have a basic understanding of the sickle cell disorder.
John James, chief executive of the Sickle Cell Society, said: 'This report is crystal clear in its framing of the huge challenges faced by sickle cell patients in London, when they are at their most vulnerable.
'It is indefensible that people with a serious and life-threatening health condition are receiving poor care, delays and unhelpful attitudes from ambulance staff.
'We welcome LAS commissioning this report, and their commitment to the development of an action plan to address its recommendations. It is essential that this leads to real, lasting change.'
There are around 17,500 people with sickle cell disease in the UK.
It is particularly common in people with an African or Caribbean family background.
Symptoms can include very severe pain, serious and life-threatening infections and anaemia.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
4 days ago
- The Guardian
Colonial ideas of beauty: how skin lightening products are linked to cancer in black African women
Two months after first going to hospital, a 65-year-old woman was dead – and her doctors are blaming the cosmetic creams she used on her face and body for decades. The anonymous patient, from Togo, is one of a string of recent cases reported in medical journals of cancers in black African women linked to skin-lightening creams and lotions, prompting dermatologists to call for better regulation. The melanin found in darker skin typically offers some protection against the sun damage which can cause cancers. 'Patients with black skin have a natural SPF of about 15, just by having pigmented skin,' says Prof Ncoza Dlova, head of dermatology at the University of KwaZulu-Natal, South Africa,. 'If they remove that melanin [with skin lightening creams], they're actually removing the natural protection.' Estimates of skin lightening product use in African countries range from 25% to 80% of women. Lighter skin is often seen as more desirable, in a trend with complex drivers including values imported in the colonial era. Dlova and colleagues are writing up a paper citing more than 55 cancer cases, from countries including Mali and Senegal. 'If we are getting self-induced skin cancer, then that's a red flag and worrying,' says Dlova. 'We have to do something about it.' The market for skin lightening product is growing, with analysts predicting that the current market size of US$10.7bn (£8bn) will reach US$18.1bn by 2033. There are even reports of the products being used on babies and young children. For Dlova, they are 'a health hazard that needs to be addressed'. Almost every day, she says, her clinic in Durban will see someone with a skin problem linked to lightening products. 'Of course, not all of them are coming with skin cancer … They come in with fungal infections that are resistant to the common treatment that we normally use. They present with pimples, referred to as steroid-induced acne, as well as rosacea. Some present with permanent stretch marks; all these complications are extremely common.' The Togo patient had three large, painful, cancerous tumours on her neck, which she had tried to treat with antibiotics, antiseptics and traditional herbal poultices with no success before going to hospital. One of the tumours was removed, but the others were too close to blood vessels and she could not afford the recommended chemotherapy. She told her doctors she had used creams that included topical hydroquinone and highly potent corticosteroids for about 30 years. In another series of eight cancers, reported in Senegal, the women had used similar products for about 20 years on average. Two of those patients died. Hydroquinone as a skin lightener has been banned in South Africa since 1990, and other African countries including Rwanda, Ivory Coast, Tanzania, Kenya, and Ghana followed suit. Those bans were prompted by serious concerns about an irreversible form of skin damage called ochronosis. But regulation is often weak, and the products are reportedly still available from street vendors and cosmetic shops. The use of steroids in skin lighteners is a newer phenomenon. Topical steroids are used in dermatology to treat inflammatory skin conditions such as eczema, but a side-effect is that they make skin lighter, a fact exploited for their use in cosmetics. If the two problematic ingredients are used together they can have a 'synergistic effect', Dlova says. The International League of Dermatological Societies (ILDS) has published an alert warning about the dangers of misuse of potent topical steroids, and is calling for governments to better regulate the products. The problem goes beyond Africa, says the ILDS president Prof Henry Lim, with the problem first raised by its members in India. After South Africa's hydroquinone ban, there was a lull in how frequently dermatologists encountered complications of skin bleaching, Dlova says 'but again, in the last 10 years there was just a sudden eruption of the complications of skin bleaching again. Skin cancer per se had not been described before, it's only been described recently. So obviously, things have got worse – because from irreversible pigmentation [ochronosis] to skin cancer, those are really red flags implying that we need to do something about it.' While the desire for lighter skin is not new, Dlova suspects the rise of social media over the past decade has led to increased use, pointing to smartphone filters that make skin look smoother and lighter. Tackling the issue will require action from many sectors – not only regulatory agencies. 'Marketing, social media and media all have a role to play – fashion, celebrities and all of that. If they use black models who are lighter in skin colour, the message they are conveying is that you are prettier, you can be a model, you are more attractive if you are lighter. So we need to ensure that the advertisements include diverse skin colours when they are choosing their models,' says Dlova. She also wants to see skin health education in preschools to teach children to be proud of their natural skin, and to get across the message of using sunscreen. Some black patients will have skin challenges including pigmentation disorders, she says, which may require creams with lightening ingredients. But these should be used under medical supervision. Part of the ILDS advocacy will be asking pharmaceutical companies to make those prescription products more affordable, so that people do not need to turn to cheaper off-the-shelf products that may be dangerous.
Economist
24-07-2025
- Economist
The pandemic preparedness dividend—investing today to prevent and mitigate tomorrow's pandemics
Announcing the Africa Health Security Index The world remains dangerously unprepared for the next biological threat. The 2021 Global Health Security (GHS) Index gave African nations an average score of 29 out of a possible 100, which leaves significant room for improvement. The Africa Health Security (AHS) Index is a comprehensive, independent assessment of epidemic and pandemic preparedness across Africa. The AHS Index is developed by NTI | bio, in partnership with the Brown University Pandemic Center and Economist Impact, in collaboration with Science for Africa Foundation, the University of the Witwatersrand (Johannesburg, South Africa) and the University of Tunis El Manar (Tunis, Tunisia). Funding is provided by the Gates Foundation. The index, launching in 2026, will enable leaders to measure, finance and advance improvements in health security and create an evidence-based accountability framework to track progress towards better epidemic and pandemic preparedness in Africa.
Economist
24-07-2025
- Economist
Rethinking the war on AIDS
AIDS AND HIV, the virus that causes it, once sparked fear across the world. Apocalyptic forecasters in early 2002 reckoned that in some southern African countries half of new mothers would soon die of AIDS. Tens of millions of lives would be lost over coming decades. Economies would be devastated. Instead, what was arguably the most effective foreign-aid programme ever was introduced in 2003 by President George W. Bush.
